1. Home
  2. ELMD vs CHRS Comparison

ELMD vs CHRS Comparison

Compare ELMD & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Electromed Inc.

ELMD

Electromed Inc.

HOLD

Current Price

$38.08

Market Cap

208.1M

Sector

Health Care

ML Signal

HOLD

Logo Coherus BioSciences Inc.

CHRS

Coherus BioSciences Inc.

HOLD

Current Price

$1.46

Market Cap

209.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ELMD
CHRS
Founded
1992
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
208.1M
209.8M
IPO Year
2010
2014

Fundamental Metrics

Financial Performance
Metric
ELMD
CHRS
Price
$38.08
$1.46
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
4
Target Price
$36.00
$5.51
AVG Volume (30 Days)
48.4K
845.0K
Earning Date
05-12-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
46.55
472.00
EPS
0.91
N/A
Revenue
$54,716,000.00
N/A
Revenue This Year
$15.59
$73.08
Revenue Next Year
$11.51
$30.94
P/E Ratio
$40.92
N/A
Revenue Growth
13.83
N/A
52 Week Low
$17.73
$0.72
52 Week High
$40.00
$2.62

Technical Indicators

Market Signals
Indicator
ELMD
CHRS
Relative Strength Index (RSI) 61.62 45.48
Support Level $23.47 $1.37
Resistance Level $40.00 $1.75
Average True Range (ATR) 1.98 0.08
MACD -0.38 0.00
Stochastic Oscillator 64.75 41.90

Price Performance

Historical Comparison
ELMD
CHRS

About ELMD Electromed Inc.

Electromed Inc is a United States-based company that develops, manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest Airway Clearance System and related products, to patients with compromised pulmonary function with a commitment to excellence and compassionate service. The SmartVest System features a programmable air pulse generator, a therapy garment worn over the upper body and a connecting hose, which together provide safe, comfortable, and effective airway clearance therapy.

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.

Share on Social Networks: